Developing cancer therapies by inhibiting kinases
Our work is focused on developing cancer therapies by inhibiting kinases, a class of enzymes that have proven to be the most tractable drug targets in oncology. Over the past decade, kinase inhibitors have remarkably improved the treatment of cancer and have radically changed the course of history by improving cancer cure rates. When kinases are active they fuel cancer cell growth and promote the spread of cancer to different parts of the body. The key is finding the essential kinase that is responsible for the growth of each cancer type and then blocking its activity. By determining which kinase is the Achilles heel for a particular type of cancer, we can deliver personalized, targeted therapies with better treatment results.